Liposome-based diagnostic and therapeutic applications for pancreatic cancer

Tools

Raza, Faisal and Evans, Lauren and Motallebi, Mahzad and Zafar, Hajra and Pereira-Silva, Miguel and Saleem, Kalsoom and Peixoto, Diana and Rahdar, Abbas and Sharifi, Esmaeel and Veiga, Fransisco and Hoskins, Clare and Paiva-Santos, Ana Cláudia (2022) Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomaterialia. ISSN 1742-7061 (https://doi.org/10.1016/j.actbio.2022.12.013)

[thumbnail of Raza-etal-AB-2022-Liposome-based-diagnostic-and-therapeutic-applications-for-pancreatic-cancer]
Preview
 Text. Filename: Raza_etal_AB_2022_Liposome_based_diagnostic_and_therapeutic_applications_for_pancreatic_cancer.pdf
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (1MB)| Preview

Abstract

Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled as incurable. Chemotherapy continues to be the most popular treatment yet yields a very poor prognosis. The main barriers such as inefficient drug penetration and drug resistance, have led to the development of drug carrier systems. The benefits, ease of fabrication and modification of liposomes render them as ideal future drug delivery systems. This review delves into the versatility of liposomes to achieve various mechanisms of treatment for pancreatic cancer. Not only are there benefits of loading chemotherapy drugs and targeting agents onto liposomes, as well as mRNA combined therapy, but liposomes have also been exploited for immunotherapy and can be programmed to respond to photothermal therapy. Multifunctional liposomal formulations have demonstrated significant pre-clinical success. Functionalising drug-encapsulated liposomes has resulted in triggered drug release, specific targeting, and remodeling of the tumor environment. Suppressing tumor progression has been achieved, due to their ability to more efficiently and precisely deliver chemotherapy. Currently, no multifunctional surface-modified liposomes are clinically approved for pancreatic cancer thus we aim to shed light on the trials and tribulations and progress so far, with the hope for liposomal therapy in the future and improved patient outcomes.

ORCID iDs

Raza, Faisal, Evans, Lauren, Motallebi, Mahzad, Zafar, Hajra, Pereira-Silva, Miguel, Saleem, Kalsoom, Peixoto, Diana, Rahdar, Abbas, Sharifi, Esmaeel, Veiga, Fransisco, Hoskins, Clare ORCID logoORCID: https://orcid.org/0000-0002-7200-0566 and Paiva-Santos, Ana Cláudia;
  • Item type:Article
    ID code:83506
    Dates:
    Date
    Event
    12 December 2022
    Published
    12 December 2022
    Published Online
    7 December 2022
    Accepted
    Notes:Journal 'pre-proof' published online 12 December 2022
    Subjects:Medicine > Therapeutics. Pharmacology
    Department:Faculty of Science > Pure and Applied Chemistry
    Depositing user: Pure Administrator
    Date deposited:13 Dec 2022 11:42
    Last modified:12 Dec 2024 14:08
    URI:https://strathprints.strath.ac.uk/id/eprint/83506
CORE (COnnecting REpositories)